JP2022544613A5 - - Google Patents

Info

Publication number
JP2022544613A5
JP2022544613A5 JP2022509723A JP2022509723A JP2022544613A5 JP 2022544613 A5 JP2022544613 A5 JP 2022544613A5 JP 2022509723 A JP2022509723 A JP 2022509723A JP 2022509723 A JP2022509723 A JP 2022509723A JP 2022544613 A5 JP2022544613 A5 JP 2022544613A5
Authority
JP
Japan
Prior art keywords
hepatitis
vaccine
unit dose
dengue
dengue fever
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544613A (ja
JP7731344B2 (ja
Filing date
Publication date
Priority claimed from US16/561,953 external-priority patent/US11590221B2/en
Application filed filed Critical
Priority claimed from PCT/US2020/020991 external-priority patent/WO2021034349A1/en
Publication of JP2022544613A publication Critical patent/JP2022544613A/ja
Publication of JP2022544613A5 publication Critical patent/JP2022544613A5/ja
Priority to JP2024177535A priority Critical patent/JP2025032070A/ja
Application granted granted Critical
Publication of JP7731344B2 publication Critical patent/JP7731344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509723A 2019-08-16 2020-03-04 デング熱及びa型肝炎を予防するための方法 Active JP7731344B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177535A JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
IDP00201907241 2019-08-16
IDPID2019-07241 2019-08-16
EP19195692.9 2019-09-05
USPCT/US2019/049749 2019-09-05
US16/561,953 US11590221B2 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
EP19195692.9A EP3620174B1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
PCT/US2019/049749 WO2020051334A1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
US16/561,953 2019-09-05
PCT/US2020/020991 WO2021034349A1 (en) 2019-08-16 2020-03-04 Methods for preventing dengue and hepatitis a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177535A Division JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Publications (3)

Publication Number Publication Date
JP2022544613A JP2022544613A (ja) 2022-10-19
JP2022544613A5 true JP2022544613A5 (cg-RX-API-DMAC7.html) 2023-03-09
JP7731344B2 JP7731344B2 (ja) 2025-08-29

Family

ID=74660757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509723A Active JP7731344B2 (ja) 2019-08-16 2020-03-04 デング熱及びa型肝炎を予防するための方法
JP2024177535A Pending JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177535A Pending JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Country Status (10)

Country Link
EP (1) EP4013451A1 (cg-RX-API-DMAC7.html)
JP (2) JP7731344B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220049023A (cg-RX-API-DMAC7.html)
CN (1) CN114555113A (cg-RX-API-DMAC7.html)
AU (3) AU2020331884B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147807A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022001742A (cg-RX-API-DMAC7.html)
PH (1) PH12022550261A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260167703A1 (en) * 2022-11-02 2026-06-18 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
DK2054428T3 (da) 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) * 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法

Similar Documents

Publication Publication Date Title
Stevens et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission
Mitus et al. Attenuated measles vaccine in children with acute leukemia
Ni et al. Hepatitis B vaccination in children: the Taiwan experience
Zhang et al. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine
Stevens et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization
Parkman et al. Summary of clinical trials of influenza virus vaccines in adults
Ghendon WHO strategy for the global elimination of new cases of hepatitis B
US10092640B2 (en) Combination heptavalent vaccine
Xu et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection
SI9300271A (en) Combinated vaccine combinations containing hepatitis b as a vaccine component useful for treating hepatitis b infections
JP2016020361A (ja) ワクチン
Esposito et al. Hexavalent vaccines for immunization in paediatric age
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
Dennehy Active immunization in the United States: developments over the past decade
Nirmal et al. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine
Ward et al. Hepatitis B vaccines
Gil et al. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL. U.). A controlled study in adults
EP1187631B1 (en) Prevention of type 1 diabetes and other non-polio enterovirus diseases
US7972592B2 (en) Prevention of type 1 diabetes and other non-polio enterovirus diseases
Doerr et al. Vaccination against infectious diseases: what is promising?
Sonoyama et al. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
Kollaritsch et al. Principles of immunization
JP2020536107A5 (cg-RX-API-DMAC7.html)
Sumaya et al. Persistence of antibody after the administration of influenza vaccine to children with cancer
Ward Hepatitis B vaccines